Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for November 9, 2021, to discuss its financial results for Q3 2021, ended September 30, and provide a business update. Participants can join via telephone or access the webcast through the company’s website. Selecta focuses on developing tolerogenic therapies using its ImmTOR™ platform, aimed at improving the efficacy of biologic treatments and restoring immune tolerance in autoimmune diseases.

Positive

• Selecta's ImmTOR™ platform has proven capabilities in inducing tolerance to immunogenic proteins, potentially amplifying biologic therapies' efficacy.
• The company has several proprietary and partnered programs targeting enzyme therapies, gene therapies, and autoimmune diseases.

Negative

• None.

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147803. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (Nasdaq: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com 

 

FAQ

What are Selecta Biosciences' financial results for Q3 2021?

Selecta Biosciences will disclose its Q3 2021 financial results during the conference call on November 9, 2021.

When is Selecta Biosciences' conference call scheduled?

The conference call is scheduled for November 9, 2021, at 8:30 a.m. ET.

How can I access the Selecta Biosciences conference call?

Individuals can join the call by dialing 844-845-4170 (domestic) or 412-717-9621 (international), with a replay available for one week afterward.

What is the purpose of Selecta Biosciences' upcoming conference call?

The call will discuss financial results for Q3 2021 and provide a business update on their operations.